| dc.description.abstract | Breast cancer is the most diagnosed cancer in women. In general, patients with breast cancer have high aggression, poor prognosis, and high recurrence rate. Based on the previous research efforts, treatment by early detection with target chemotherapy may effectively reduce the risk of recurrence. However, anticancer drug-induced side effects seriously interfere the physiological conditions of the patients and may adversely affect the therapeutic efficacy consequently. Therefore, we aim to achieve effective treatment for breast cancer through a target therapy with reduced the use of chemo-drugs. In this study, we have developed a type of HER2 target indocyanine green (ICG)-camptothecin (CPT)-encapsulated perfluorocarbon double-nanoagents (HICPDNAs) that may provide both chemotherapy and phototherapy upon light illumination. Through DLS analysis, the size and zeta potential of the HICPDNAs is about 2268.6 ± 20 nm and -25.7 ± 5 mV, respectively. The encapsulation efficiency for ICG and CPT is 97.842 ± 1.540% and 46.400 ± 5.780%, respectively. In comparison to freely dissolved ICG, the HICPDNAs with equal dose of ICG under near infrared (NIR) irradiation (808 nm, 6 W/cm2) can generate similar hyperthermia effect but significantly enhanced amount of singlet oxygen, showing a high potential for use in photothermal and photodynamic therapeutic applications. In the in vitro cell experiment, HICPDNAs showed specificity with two HER2-positive breast cancer cells (MDA-MB-453 and BT-474)，and in the cytotoxicity test, it also showed a better toxic effect than the free CPT solution. In the animal experiments, ICG-CPT-encapsulated perfluorocarbon double-nanoagents (ICPDNAs) showed better tumor suppression effects than the free CPT solution and ICG particles groups (ICG-encapsulated perfluorocarbon double-nanoagents; IPDNAs). ICPDNAs also didn’t cause serious damage to other important organs in the animal experiments. In this study, we have proved that ICPDNAs are effective in the treatment of breast cancer and have sufficient safety in animals, showing that ICPDNAs is expected to have further development in the future. | en_US |